

CNS Working Group

**Thursday, May 11, 2023
5:15 PM - 7:45 PM PT**

Welcome & Introductions

*Manmeet S. Ahluwalia
Miami Cancer Institute*

CNS Cell-Free DNA Methylation Marker for Diagnosis and Monitoring

*Houtan Noushmehr
Henry Ford*

Lessons from Phase 0 Trials - The Ivy Experience

*Nader Sanai
Barrow/Ivy*

FGFR/TACC Fusion Study in GBM

*Patrick Wen
Dana Farber, Harvard*

Predicting Venous Thromboembolism in Adult-Type Diffuse Glioma Patients

*Craig Horbinsky
Northwestern University*

Lessons from NRG Brain Tumor Committee

*Minesh Mehta
Miami Cancer Institute*

Lessons from ECOG Brain Tumor Committee

*David Schiff
University of Virginia*

A Phase 0 Trial of Repurposed Azoles for Glioblastoma: Concept, Execution, and Challenges

*Alireza Mansouri
Penn State Cancer Institute*

A Phase II Study of Atezolizumab and Tocilizumab with Radiotherapy in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

*Tony J.C. Wang
Columbia University Irving
Medical Center*

Phase I Trial of TRC 102 and Temzolomide with Radiation in Patients with Newly Diagnosed MGMT Methylated Glioblastoma

*Manmeet S. Ahluwalia
Miami Cancer Institute*